Celldex Therapeutics CLDX Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Celldex Therapeutics's change in other liabilities?
- Celldex Therapeutics (CLDX) reported change in other liabilities of -$1.36M in Q1 2026.
- How has Celldex Therapeutics's change in other liabilities changed year-over-year?
- Celldex Therapeutics's change in other liabilities decreased by 124.8% year-over-year, from -$604K to -$1.36M.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.